QRG Capital Management Inc. Acquires 7,306 Shares of Sanofi (NASDAQ:SNY)

QRG Capital Management Inc. grew its holdings in Sanofi (NASDAQ:SNY) by 5.1% during the 1st quarter, Holdings Channel reports. The firm owned 150,816 shares of the company’s stock after purchasing an additional 7,306 shares during the period. QRG Capital Management Inc.’s holdings in Sanofi were worth $8,364,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of SNY. Lee Danner & Bass Inc. bought a new position in shares of Sanofi in the 4th quarter valued at about $31,000. Bessemer Group Inc. raised its position in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after acquiring an additional 242 shares during the period. Sierra Ocean LLC acquired a new stake in shares of Sanofi in the 4th quarter valued at approximately $44,000. UMB Bank n.a. raised its position in shares of Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock valued at $62,000 after acquiring an additional 264 shares during the period. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Sanofi in the 4th quarter valued at approximately $76,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of SNY stock opened at $48.22 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The company has a market capitalization of $118.26 billion, a P/E ratio of 17.22, a price-to-earnings-growth ratio of 0.99 and a beta of 0.50. The company’s 50 day moving average price is $51.42 and its two-hundred day moving average price is $52.04. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same period last year, the company posted $1.78 EPS. The business’s quarterly revenue was down 11.0% on a year-over-year basis. On average, analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were issued a $2.0369 dividend. The ex-dividend date of this dividend was Friday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi’s dividend payout ratio (DPR) is 57.14%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. BNP Paribas assumed coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price target on the stock. Guggenheim reiterated a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, three have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.